Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y2D2
UPID:
S35A3_HUMAN
Alternative names:
Golgi UDP-GlcNAc transporter; Solute carrier family 35 member A3
Alternative UPACC:
Q9Y2D2; A8K3F8; D3DT54; Q68CR2; Q9BSB7
Background:
The UDP-N-acetylglucosamine transporter, also known as Solute carrier family 35 member A3 (SLC35A3), plays a crucial role in cellular function by transporting UDP-GlcNAc into the Golgi apparatus. This process is essential for the synthesis of complex N-glycans and keratan sulfate, contributing to cell surface glycosylation.
Therapeutic significance:
SLC35A3's involvement in the disease 'Arthrogryposis, impaired intellectual development, and seizures' highlights its potential as a therapeutic target. The disease's association with altered glycosylation patterns suggests that modulating SLC35A3 activity could offer new avenues for treatment.